Consequently, targeting miR-29b/DNMT3B/PI3K/AKT signaling may present a promising strategy for augmenting the therapeutic efficacy of cisplatin in the context of PCa treatment [92]. The gene discussed is DNMT3B; the disease is posterior cortical atrophy.